GeneHealth - Your precision medicine

Exanthema Subitum

Disease Details

Family Health Simplified

Buy Membership

Description: Exanthema subitum, also known as roseola, is a common, contagious viral infection primarily affecting infants and young children, characterized by several days of high fever followed by a distinctive rash as the fever subsides.
Type: Exanthema subitum, also known as roseola infantum or sixth disease, is a viral infection. It is caused by the human herpesvirus 6 (HHV-6) and sometimes human herpesvirus 7 (HHV-7). Regarding genetic transmission, exanthema subitum is not inherited genetically but is instead transmitted from person to person, typically through respiratory secretions.
Signs And Symptoms: **Signs and Symptoms of Exanthema Subitum (Roseola Infantum):**

1. **High Fever**: Often sudden onset, usually lasting 3 to 5 days.
2. **Rash**: Appears as the fever subsides, characterized by small pink spots or patches mostly on the trunk and neck, potentially spreading to the face and limbs.
3. **Irritability**: Common in children due to discomfort.
4. **Mild Respiratory Symptoms**: Such as a runny nose or cough.
5. **Swollen Eyelids**: Sometimes observed.
6. **Diarrhea**: In some cases.
7. **Fatigue**: General tiredness.
8. **Mild sore throat**: Occasionally present.

The rash typically lasts for a few hours to a couple of days and may be more noticeable after a bath or when the child is warm.
Prognosis: Children infected with roseola generally have a good prognosis. Most recover without intervention and without long-term effects.
Onset: Exanthema subitum, also known as roseola infantum or sixth disease, typically begins with a sudden high fever lasting for 3-5 days. After the fever subsides, a characteristic rash appears, usually starting on the trunk and then spreading to the limbs and neck. The rash consists of small, rose-pink spots that may be slightly raised.
Prevalence: Exanthema subitum, also known as roseola infantum or sixth disease, has a high prevalence among infants and young children. Most children are infected by human herpesvirus 6 (HHV-6) or, less commonly, human herpesvirus 7 (HHV-7) by age 2. Serological studies indicate that up to 90% of children have been infected by these viruses by the time they reach early childhood.
Epidemiology: Between the two types of human herpesvirus 6, HHV-6B has been detected much more frequently in hosts. HHV-6B has been shown to affect about 90% of children before the age of 3. Out of these, 20% develop symptoms of roseola, also known as exanthem subitum.Roseola affects girls and boys equally worldwide year-round. Roseola typically affects children between six months and two years of age, with peak prevalence in children between 7 and 13 months old. This correlates with the decrease in maternal antibodies, thus virus protection, that occurs at the age of 6 months. Out of all emergency department visits for children between the ages of 6 months and 12 months who have fever, twenty percent of these are due to HHV-6.Many children who have been exposed and infected can present without symptoms, which makes determining the incidence within the population difficult.
Intractability: Exanthema subitum, also known as roseola infantum or sixth disease, is typically not considered intractable. It usually resolves on its own without complications, especially in children. The primary treatment involves managing symptoms like fever, and supportive care is generally sufficient.
Disease Severity: Exanthema subitum, also known as roseola infantum, typically presents as a mild illness.
Healthcare Professionals: Disease Ontology ID - DOID:0050495
Pathophysiology: Pathophysiology of exanthema subitum (also known as roseola infantum or sixth disease) involves infection with human herpesvirus 6 (HHV-6), and occasionally human herpesvirus 7 (HHV-7). After an incubation period of about 5-15 days, the virus infects leukocytes and spreads to other organs via the bloodstream. This leads to a high fever lasting 3-5 days, followed by a sudden drop in temperature and the appearance of a characteristic pinkish-red maculopapular rash primarily on the trunk, which then spreads to the extremities. The fever often resolves just as the rash appears. The exact mechanism of how the virus causes these clinical features is still under study.
Carrier Status: Exanthema subitum, also known as roseola infantum or sixth disease, is primarily caused by human herpesvirus 6 (HHV-6) and sometimes by human herpesvirus 7 (HHV-7). The concept of a "carrier status" for HHV-6 and HHV-7 is not typically used because most people are infected with these viruses early in life. After primary infection, the viruses remain latent in the body and can potentially reactivate later. Hence, nearly all adults carry the virus in a latent form.
Mechanism: Exanthema subitum, also known as roseola infantum or sixth disease, is primarily caused by human herpesvirus 6 (HHV-6) or, less commonly, human herpesvirus 7 (HHV-7).

**Mechanism:**
The primary mechanism of exanthema subitum involves the viral infection of the host. The virus is typically transmitted through respiratory droplets from an infected person. Once inside the body, HHV-6 infects T cells, macrophages, and other cell types, leading to viremia (the presence of the virus in the bloodstream). This viremia is responsible for the high fever and systemic symptoms seen in the early phase of the disease. After the fever subsides, a characteristic red rash appears, largely on the trunk and neck, which then spreads to other areas.

**Molecular Mechanisms:**
1. **Viral Entry:** HHV-6 enters host cells via binding to the CD46 receptor, which is ubiquitously expressed on various cell types, facilitating widespread infection.
2. **Immune Response Modulation:** During infection, HHV-6 can downregulate the expression of immune-regulatory molecules, such as MHC class I and II, helping it evade the host immune response.
3. **Latency:** After the acute phase of the infection, HHV-6 can establish latency within the host cells, particularly in monocytes/macrophages and central nervous system glial cells. The virus integrates its genomic DNA into the telomeres of host chromosomes, enabling it to persist long-term and potentially reactivate under certain conditions.

These molecular interactions and the virus's ability to modulate the host immune response play critical roles in the pathogenesis of exanthema subitum.
Treatment: Most cases of HHV-6 infection improve on their own. Because of this, supportive care is the mainstay treatment. The febrile phase can be managed using acetaminophen to control fever and prevent spikes in temperature which can lead to febrile seizures. In the case of febrile seizures, medical advice should be sought, and treatment aggressively pursued. Antiepileptic drugs are not recommended for patients who develop seizures from Roseola. Once children have entered the rash phase, reassurance is important as this indicates resolution of the infection.If encephalitis occurs in immunocompromised children, ganciclovir or foscarnet have inconsistently shown usefulness in treatment. Treatment of children who are immunocompromised centers around decreasing their levels of immunosuppression as much as possible.
Compassionate Use Treatment: Exanthema subitum, also known as roseola infantum or sixth disease, is a common viral infection in young children typically caused by human herpesvirus 6 (HHV-6) and less frequently by human herpesvirus 7 (HHV-7). It usually resolves on its own without the need for specific treatment other than supportive care to manage symptoms like fever.

There are no well-established compassionate use treatments or widely recognized off-label or experimental treatments for exanthema subitum. The primary approach is supportive care, including antipyretics like acetaminophen or ibuprofen to reduce fever and ensuring adequate hydration. Antiviral therapy is not generally recommended as the condition is usually self-limiting in immunocompetent children.

In rare cases of severe or persistent infection, particularly in immunocompromised individuals, antivirals such as ganciclovir or foscarnet may be considered, but this would be an off-label use and should be done under the guidance of a healthcare professional. Always consult with a healthcare provider for the most appropriate management for individual cases.
Lifestyle Recommendations: Exanthema subitum, also known as roseola infantum or sixth disease, primarily affects infants and young children. Here are some lifestyle recommendations for managing the condition:

1. **Hydration**: Ensure the child stays well-hydrated by giving plenty of fluids such as water, oral rehydration solutions, or clear broths.

2. **Rest**: Encourage the child to rest as much as possible to aid in recovery.

3. **Comfort Measures**: Use lukewarm sponge baths or a cool, damp cloth to help reduce fever and provide comfort.

4. **Fever Management**: Administer age-appropriate fever reducers like acetaminophen or ibuprofen, but always consult a healthcare provider for proper dosing.

5. **Monitoring**: Keep an eye on the child's symptoms, particularly if the fever is high or persistent, as complications are rare but possible.

6. **Nutrition**: Offer light, easily digestible foods if the child is interested in eating.

7. **Isolation**: Since roseola is contagious, try to limit the child's contact with other children until the fever has resolved and the rash has faded to prevent spreading the infection.

Proper care and close monitoring during the illness will help ensure a smooth recovery.
Medication: Exanthema subitum, also known as roseola or sixth disease, is typically a mild viral infection caused by human herpesvirus 6 (HHV-6) or, less commonly, human herpesvirus 7 (HHV-7). In most cases, it resolves on its own without the need for specific antiviral medication. Treatment focuses on supportive care to alleviate symptoms. This may include:

- **Antipyretics:** Medications such as acetaminophen or ibuprofen to reduce fever.
- **Hydration:** Ensuring the child is well-hydrated.
- **Rest:** Encouraging sufficient rest and comfort.

Antibiotics are not effective, as this is a viral infection. Always consult with a healthcare provider for the most appropriate management.
Repurposable Drugs: Exanthema subitum, also known as roseola infantum or sixth disease, is a common viral infection in young children, typically caused by human herpesvirus 6 (HHV-6) or, less frequently, human herpesvirus 7 (HHV-7). There are no specific repurposable drugs that have been definitively approved for treating exanthema subitum. Management typically focuses on supportive care, including fever reduction with acetaminophen or ibuprofen and ensuring adequate fluid intake. Antiviral medications such as ganciclovir or foscarnet might be considered in severe or complicated cases, particularly in immunocompromised patients, but these are not standard treatments for otherwise healthy children with roseola.
Metabolites: Exanthema subitum, also known as roseola infantum or sixth disease, is a viral infection primarily caused by human herpesvirus 6 (HHV-6) and sometimes by human herpesvirus 7 (HHV-7). Detailed studies on specific metabolites directly linked to exanthema subitum are limited. The condition primarily involves the immune response rather than significant alterations in metabolic pathways that would be characterized by distinct metabolites. If there is a particular aspect of metabolism or a related subject you are interested in, let me know so I can provide a more tailored response.
Nutraceuticals: Exanthema subitum, also known as roseola infantum, is a common viral infection typically affecting infants and young children. There is limited research on the use of nutraceuticals specifically for treating roseola. Management usually focuses on symptomatic relief, such as using antipyretics for fever and ensuring adequate hydration. Always consult a healthcare professional for guidance on the use of nutraceuticals in children.
Peptides: Exanthema subitum, also known as roseola infantum or sixth disease, is caused by human herpesvirus 6 (HHV-6) and sometimes HHV-7. It is characterized by a sudden high fever followed by a rash as the fever subsides. While detailed peptide information specific to HHV-6 is complex, the virus’s proteins and peptides involved in its infection and replication processes could potentially be targets for diagnostic or therapeutic interventions. Generally, antiviral agents and supportive care are used rather than peptide-based treatments. For research-related applications, certain viral peptides may be studied for vaccine development or immunological studies.